Julie Kim

Grünenthal

Uli Brödl

Grünenthal has appointed Uli Brödl as chief scientific officer and member of the company’s corporate executive board. Brödl joins Grünenthal from Boehringer Ingelheim, where he served as corporate senior vice president, head of global clinical development and operations, and a member of the company’s venture fund investment committee.

Kite Pharma

Brian Heath

Kite Pharma has appointed Brian Heath as head of global commercial. Heath joins the Gilead company after spending 16 years at Amgen. He most recently served as vice president and general manager of Amgen’s US oncology business unit and previously led the company’s Canadian operations. He also held positions at Eli Lilly earlier in his career.

Verastem Oncology

Matthew Ros

Verastem Oncology has appointed Matthew Ros as chief operating officer. Ros brings more than 35 years of experience to the role, which he takes on after most recently serving as chief executive officer and board director at FORE Biotherapeutics. Prior to this, he held executive leadership roles at companies including Epizyme and Sanofi-Genzyme, now Sanofi.

Outrun Therapeutics

Matthew Fyfe

Outrun Therapeutics has appointed Matthew Fyfe as chief scientific officer. Fyfe has over 25 years of experience in drug discovery and development. He most recently served as senior vice president of therapeutics at Storm Therapeutics. Prior to this, he was vice president and head of medicinal sciences at Sitryx Therapeutics and held positions at TopiVert and Oryzon.

Allogene Therapeutics

Benjamin Beneski

Allogene Therapeutics has appointed Benjamin Beneski as senior vice president and chief technical officer. Beneski has held roles of increasing responsibility over more than five years at Allogene, including his most recent position of vice president of product development and manufacturing. He also previously held leadership roles at Vir Biotechnology and Amgen.

Averna Therapeutics

Thomas Barnes

Averna Therapeutics has appointed Thomas Barnes as chief executive officer and director. Barnes takes on the role after most recently serving as chief executive officer of Orna Therapeutics. He was previously chief scientific officer and a member of the founding team at Intellia Therapeutics and co-founded or played a key role in launching several biotech companies earlier in his career.

Roche

Wafaa Mamilli

Roche has appointed Wafaa Mamilli as chief digital technology officer. Mamilli, who will also serve as a member of Roche's enlarged corporate executive committee, joins the company from Zoetis. She previously spent over two decades in various international roles at Eli Lilly, culminating in her position as global chief information officer for Lilly's business units.

UKHSA

Isabel Oliver

The UK Health Security Agency (UKHSA) has appointed Isabel Oliver as chief medical officer for Wales. Oliver has most recently been serving as UKHSA’s director general of science and research, and chief scientific officer. She previously held multiple roles at Public Health England, culminating in her role as director of its national infection service.